Ginkgo Bioworks Holdings Inc vs Eaton Corporation plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M), while Eaton Corporation plc trades at $464.19 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 341.7× Ginkgo Bioworks Holdings Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ETN | |
|---|---|---|
Market Cap | $505.73M | $172.82B |
Sector | Health | Technology |
52-Week High | $16.14 | $459.29 |
52-Week Low | $5.48 | $315.82 |
Enterprise Value | $607.68M | $193.45B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.
Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →